caseintelcaseintel
← Back to Dashboard
Litigation Stage Tracker
Early / Monitoring

Fluoroquinolone

BorderlineFLAT
Pharma
250+
Total Cases

Causation

Fluoroquinolone antibiotics cause mitochondrial toxicity and oxidative stress leading to tendon rupture, peripheral neuropathy, aortic aneurysm/dissection, and CNS damage — collectively termed fluoroquinolone-associated disability (FQAD). The FDA issued a black box warning in 2008 for tendon rupture, strengthened it in 2013 for peripheral neuropathy, and added aortic aneurysm warnings in 2018. Plaintiffs allege manufacturers knew of serious adverse effects for decades and failed to adequately warn.

Defendants

EntityRoleNote
Bayer AGManufacturerCipro (ciprofloxacin) and Avelox (moxifloxacin)
Janssen Pharmaceuticals (J&J)ManufacturerLevaquin (levofloxacin) — marketed until 2017
Mylan / ViatrisGeneric ManufacturerMajor generic fluoroquinolone producer
Teva Pharmaceutical IndustriesGeneric ManufacturerGeneric ciprofloxacin and levofloxacin

Litigation Timeline

Aug 2013
FDA adds peripheral neuropathy warning — potential permanence
Jul 2016
FDA restricts fluoroquinolone use for uncomplicated infections
Dec 2018
FDA adds aortic aneurysm and dissection warning
2019
JAMA Internal Medicine: 2.4x aortic dissection risk confirmed
2020-2026
Individual and coordinated filings continue — ~250 active cases

Intelligence Signals

No signals yet. Signals populate automatically when scrapers run.

Key Facts

Status
active

Geographic Exposure

·Pre-MDL — cases filed in multiple federal districts
·D. Minn. (Levaquin cases — prior MDL 2642, now closed)
·State courts nationwide
·International litigation in Canada and EU

Eligibility Criteria

  • Took a fluoroquinolone antibiotic (Cipro, Levaquin, Avelox, or generic equivalent)
  • Diagnosed with tendon rupture, peripheral neuropathy, aortic aneurysm/dissection, or FQAD
  • Symptoms developed during or within 6 months of fluoroquinolone use
  • No pre-existing condition explaining the injury